NY-SOUNDTRAP
6.10.2020 14:02:19 CEST | Business Wire | Press release
Soundtrap today launched Soundtrap Capture , a collaborative mobile app for on-the-go music capture and creation. Built with musicians and artists in mind, the new app is an interactive, user-friendly tool that lets creators collaborate in real time, and record high-quality audio whenever and wherever inspiration strikes. Starting today, Soundtrap Capture is available globally to download for free on the iOS App Store .
“This new app is all about capturing creativity whenever, and wherever it strikes. Whether it’s walking down the street, sitting in a cafe or jamming in the studio - the Soundtrap Capture app lets artists collaborate and create right there in the moment.” - Per Emanuelsson, Director of Soundtrap at Spotify.
Soundtrap empowers high-quality collaborative music-making for people around the world, giving creators the opportunity to jam in one place - see who’s recording, vibe to ideas and discuss and react to them in real time. With the Soundtrap Capture app, turning concepts into songs has never been easier.
Developed in conjunction with artists, Soundtrap Capture is an artist-oriented experience focused on the very first step of the music creation process: the concept. It’s this early stage of the creative process - the first strains of melody, the initial ad-libbed verse, the spontaneous guitar riff - that Soundtrap aims to streamline through Soundtrap Capture.
Based on insights from thousands of musicians and their collaborators, Soundtrap set out to simplify the overly complicated music ideation process, which typically involves many musicians toggling between voice notes, messaging apps, digital audio workstations and storage destinations to get their concepts across. Equipped with built-in tools for recording, layering, real-time collaboration and storage, Soundtrap Capture replaces this multi-platform process with one efficient app.
“Empowering artists to create their best work is core to our mission at Spotify,” said Charlie Hellman, Vice President and Head of Marketplace, Spotify. “I'm excited to see Soundtrap Capture help more musicians simplify the creative process and capture sparks of inspiration.”
With an upcoming update, Soundtrap’s Studio tool will soon allow artists to collaborate seamlessly on projects between the Soundtrap Capture app and the Soundtrap Studio app on mobile or desktop. This zero-friction workflow will enable, for example, a musician to start an idea on the go via Soundtrap Capture, and then have a collaborator pick up and build on that idea using Soundtrap Studio from their computer.
Features immediately available on Soundtrap Capture include:
- Multi-track Layering: layer track recordings, instruments and vocals over one another to create different takes.
- Collaborate with Creators: invite multiple collaborators to join a project, present ideas, record and layer tracks to create songs together in real time.
- Live Storage: immediately sync and back up all projects to the Soundtrap system, and easily access them so that you never lose an idea again.
And coming later this year:
- Seamless Integration: transfer seamlessly between the Soundtrap Capture app and the Soundtrap Studio, between desktop and mobile, all without missing a beat.
ABOUT SOUNDTRAP
A part of Spotify, Soundtrap is the first cloud-based recording platform for music and podcasts that works on all operating systems, enabling people to collaborate and record together wherever they are. With an easy-to-use creation platform, Soundtrap empowers creators to build original content using a combination of software instruments, real instruments and audio recording. For more information, please visit https://www.soundtrap.com .
MEDIA ASSETS
Available for download HERE .
View source version on businesswire.com: https://www.businesswire.com/news/home/20201006005238/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom